从China供应商批量进口4-(4-Nitrophenyl)Morpholin-3-One 446292-04-2

4-(4-nitrophenyl)morpholin-3-one with the CAS number 446292-04-2 is a synthetic intermediate used in the production of rivaroxaban, a direct oral anticoagulant. The compound supplied by Wuhan Sensedawn Co., Ltd. has a minimum purity level of 98%, which is critical for maintaining consistency in downstream pharmaceutical synthesis. It is provided in a solid form suitable for laboratory and industrial applications, with packaging designed to prevent degradation during transit.

The morpholinone structure incorporates a nitro-substituted phenyl ring, which influences its reactivity in organic synthesis. Typical industry use involves its role as a key building block in the manufacture of anticoagulant drugs, where high purity reduces the risk of side reactions. Standard practice in the pharmaceutical sector requires intermediates to meet strict impurity thresholds, and this compound aligns with those expectations when sourced from reliable producers.

Pharmaceutical manufacturers and contract development organisations source this intermediate to support large-scale production of cardiovascular medications. Buyers often prioritise suppliers with consistent batch-to-batch quality, as variations can impact final drug efficacy. Logistics for this compound typically involve temperature-controlled storage and sealed containers to prevent moisture absorption, with FOB or CIF terms commonly negotiated for international shipments.

Wuhan Sensedawn Co., Ltd. is based in the Hongshan District of Wuhan, Hubei Province, with its registered address at No.2503, Building 1, Harbour of Technology, No.58 Guanggu Avenue. The company operates as an imported-tier supplier, which indicates it sources or distributes specialty chemicals for international markets. Its profile places it within a technology-focused industrial zone, which is typical for chemical intermediates suppliers in China.

The supplier’s trust tier is classified as harbor, reflecting a baseline level of verification, though its response rate is currently recorded at 0.00%, suggesting limited engagement history on the platform. No additional certifications, client references, or production capacity details are provided in the listing, so buyers are advised to request these directly. The company’s focus appears to be on pharmaceutical intermediates, with this compound offered as part of its portfolio for drug synthesis applications.